3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Hematopoietic and Lymphatic System Neoplasm
2
Smoking Cessation
1
Sedentary Behavior
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pain
1
Neoplasms
1
Myelodysplastic Syndromes
1
Motor Activity
1
Leukemia, Myeloid, Acute
1
Chronic Pain
1
Chronic Disease
1
Cervical Cancer Screening
1
Cancer Pain
1
Alzheimer Disease
1
Agnosia
1
Interventions
Magnetic Resonance Spectroscopy
49
enzalutamide
46
apalutamide
36
Specimen Handling
34
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
27
Prednisone
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
20
Radiotherapy
19
Biopsy
17
Leuprolide
15
relugolix
11
gallium 68 PSMA-11
11
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
Standard of Care
10
Nivolumab
10
cabazitaxel
9
X-Rays
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Telemedicine
×
90 days
×
Clear all
NCT06112990
2026-06-03
CREATINE-52
University of Utah
Phase 3
Recruiting
200 enrolled